I just read the newletter noting that the FDA has declined (at this time) to approve Bydureon and asked the companies involved to do additional studies on cardiovascular effects.
Why is anyone surprised at this decision??
After the Avandia disaster, the FDA is probably going to ask for similar studies for ALL new diabetes drugs. They were caught flat-footed once and are determined NOT to have that happen again (bureaucratic mindset - never be proven wrong).